Navigation Links
Pathway for Biosimilars Act Protects Patients, Promotes Competition, Preserves Innovation and Creates Quality Jobs, Lilly Says
Date:3/17/2009

INDIANAPOLIS, March 17 /PRNewswire-FirstCall/ -- Today Eli Lilly and Company (NYSE: LLY) announced its support for the Pathway for Biosimilars Act. The U.S. has a 25-year history of success with laws promoting the discovery of new, chemical-based medicines and providing an abbreviated approval process under which generic versions of those new medicines can to come to market. But Congress has yet to take that step with the most advanced new medicines, called biological drugs or simply "biologics."

Lilly said the Pathway for Biosimilars Act, reintroduced in the 111th Congress by Reps. Anna Eshoo (D-Calif.), Jay Inslee (D-Wash.) and Joe Barton (R-Texas), would successfully create a pathway that carefully weighs the needs of patients and stakeholder companies. This balance, Lilly said, would assure patients and payers the benefits that come from greater competition, preserve incentives for biotechnology innovation and foster investments that will produce more high-paying jobs in the life sciences.

"Lilly commends Representatives Eshoo, Inslee and Barton for joining together and introducing a carefully considered, balanced approach to ensuring the promise of biotech medicine becomes a reality for patients," said Robert Armitage, Lilly's senior vice president and general counsel. "Making biotech discoveries entails many years of research, massive investments and high risk. This bill makes certain that innovator companies can continue to make these types of investments in new therapies for patients, and that, once a reasonable period of time has passed for recouping its investment, generic companies can copy those innovations in a safe, scientifically sound manner."

The key provision of the Eshoo-Inslee-Barton bill striking this balance is the 14-year "data protection period." The legislation's formula would offer al
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Biogenerics Legislation Provides Critical Pathway to Affordable Access for Patients with Chronic and Complex Conditions
2. Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting
3. Millipore Launches an Interactive Biological Pathway Tool Using GeneGos Manually Curated Pathway Maps
4. Cardiovascular Side Effects of Pioglitazone and Rosiglitazone Linked to Vascular and Energy Pathways by Genomas Clinical Study
5. GEN Reports Growing Focus on PI3-Kinase Pathway in Cancer Research
6. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
7. Frost & Sullivan Awards Genpathway 2008 Healthcare Innovation Award
8. Trillium secures additional financing on the strength of lead program and proprietary position around the CD200 immunoregulatory pathway
9. Pathway Diagnostics Announces Commercial Availability of Second Generation SensiTrop(TM) II Molecular HIV Co-receptor Tropism Assay
10. Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimers Disease
11. Ingenuity Systems and Pfizer Announce Strategic Partnership for Pathway Analysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... how the receptors responsible for contractions in the bladder, ... published today in The FASEB Journal , has ... cycle of all cells in the body. The team ... and its control are weakened in ageing bladders, demonstrating ... ageing. , While currently much is known ...
(Date:8/22/2014)... August 22, 2014 Ophthalmic drug ... interesting and challenging endeavors as the anatomy, physiology ... properties to the foreign substances. Ocular drug delivery ... self medication and minimal use of needles; also ... drugs and provides specific targeting within the ocular ...
(Date:8/22/2014)... The AMA is pleased to share ... Alaska that Alaska Governor Sean Parnell has signed House ... public use of Unmanned Aircraft Systems and the continuation ... 255states that it is, “An Act relating to unmanned ... unmanned aircraft system.” It defines State of Alaska laws ...
(Date:8/21/2014)... LYNBROOK, N.Y. , Aug. 21, 2014 /PRNewswire/ ... a biopharmaceutical company developing first in class collagenase-based ... histolyticum or CCH) in the U.S. and XIAPEX ... statistically significant results from a randomized, double-blind Phase ... of cellulite, or edematous fibrosclerotic panniculopathy. The results ...
Breaking Biology Technology:Treatment for overactive bladder and irritable bowel syndrome advanced through pioneering research 2Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 4State of Alaska Signs Unmanned Aircraft Systems Bill 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 3BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 4BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 5
... , , NEW YORK, Sept. ... with Dave Champagne, Vice President and General Manager of Informatics ... Chief Engineer at HUNT Research Center and Biobank, about data ... and challenges at life sciences companies. , ...
... , , BALTIMORE, Sept. 9 ... a company engaged in the development of advanced preclinical platforms and ... present at Rodman & Renshaw,s Eleventh Annual Healthcare Conference taking place ... The company,s Chairman of the Board, Dr. David Sidransky, will present ...
... 9 Oramed Pharmaceticals,Inc. (OTCBB: ORMP.OB), a developer of ... approval from the Institutional Review Board (IRB),to commence human ... was,granted after successful pre-clinical results were reported. The trials ... Center in,Jerusalem. , Currently, all ...
Cached Biology Technology:Don't Wait to Innovate: Future Pharmaceuticals Magazine Releases Its Issue on Innovation in IT, Cell-Based Therapy and Supply Chains 2Champions Biotechnology to Present at Rodman & Renshaw's Eleventh Annual Healthcare Conference 2Champions Biotechnology to Present at Rodman & Renshaw's Eleventh Annual Healthcare Conference 3Oramed Pharmaceuticals Commences Human Clinical Trials of an Oral GLP-1 Analog 2Oramed Pharmaceuticals Commences Human Clinical Trials of an Oral GLP-1 Analog 3
(Date:8/22/2014)... Access to Research Careers) Program has announced the travel ... Practical Exercises Workshop which will be held on the ... 2014. These awards are meant to help support ... groups in the the FASEB Grant Writing Seminar & ... awards totaling $20,350. , The FASEB MARC Program is ...
(Date:8/22/2014)... Green tea polyphenols are strong antioxidants and ... protect spinal cord neurons against oxidative stress? ... Affiliated Hospital of Liaoning Medical University, China ... oxidative stress and inhibit neuronal apoptosis, indicating ... in spinal cord neurons under oxidative stress. ...
(Date:8/21/2014)... in smog-producing toxins in past decade, GTA still ... shows that while the Greater Toronto Area (GTA) ... contribute to smog, the city continues to violate ... which can cause or aggravate health problems such ... by a set of complex photochemical reactions involving ...
Breaking Biology News(10 mins):Despite a significant reduction in smog-producing toxins, the Greater Toronto Area still violates Canada's standards for ozone air pollution 2
... reconstructions of atmospheric CO2 concentrations and sea level over ... National Oceanography Centre, Southampton have found that greenhouse gas ... million) were systematically associated with sea levels at least ... determined the ,natural equilibrium, sea level for CO2 concentrations ...
... learn that plants grow toward the light. This seems straightforward, ... to grow and move in response to their environment are ... most fundamental processes in plant biologyplant movement in response to ... American Journal of Botany . Plant movements, known ...
... have cast doubt on the widely held perception that ... Blooms, or proliferations, of jellyfish can show a substantial, ... fishermen, stinging waters for tourists, even choked cooling intake ... have created a perception that the world,s oceans are ...
Cached Biology News:New study documents the natural relationship between CO2 concentrations and sea level 2Scientists join forces to bring plant movement to light 2Scientists join forces to bring plant movement to light 3Scientists join forces to bring plant movement to light 4Jellyfish experts show increased blooms are a consequence of periodic global fluctuations 2
Gap junction protein, beta 2, 26kDa (connexin 26) Antigen: Peptide...
IKKbeta/IKK-2 Polyclonal Antibody 100 ug affinity purified rabbit polyclonal antibody. Reacts with human. Tested in Western blotting....
...
Request Info...
Biology Products: